Development of an IOP-lowering gene therapy treatment for glaucoma
开发治疗青光眼的降低眼压的基因疗法
基本信息
- 批准号:10442821
- 负责人:
- 金额:$ 67.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AbbreviationsAddressAdherenceAnabolismAnimal ModelAnimalsAnteriorAqueous HumorAxenfeld-Rieger syndromeBlindnessCanis familiarisCellsCessation of lifeClinicClinicalClinical ManagementClinical TrialsComplexCorneaDataDefectDevelopmentDinoprostDiseaseDisease ProgressionDisintegrinsDoseDrainage procedureEarly DiagnosisElectrophysiology (science)ElectroretinographyEnsureEnvironmentEyeEyedropsFailureFunctional disorderFutureGene Transduction AgentGenesGlaucomaHealthHomeoboxHumanHydrophthalmosInheritedInjectionsInterventionLaboratoriesLasersLifeMediatingMetalloproteasesMichiganModelingMultimodal ImagingMusNatureNerve DegenerationNerve FibersNeuropathyOcular HypertensionOpen-Angle GlaucomaOperative Surgical ProceduresOphthalmoscopyOptic AtrophyOptic DiskOptic NerveOptical Coherence TomographyOutcomePTGS2 genePainlessPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhase I/II Clinical TrialPhenotypePhysiologic Intraocular PressurePituitary GlandProductionProstaglandin ReceptorProstaglandinsPublicationsRecombinant adeno-associated virus (rAAV)ResearchResearch PersonnelRetinaRetinal DiseasesRetinal Ganglion CellsRiskRisk FactorsSafetyScanningSerotypingTechnologyTestingTherapeuticTherapeutic InterventionThrombospondinsTissuesTopical applicationTrabecular meshwork structureTranslationsTreatment EfficacyTreatment ProtocolsUniversitiesVeterinary MedicineVisionVision researchVisual FieldsWisconsinWorkadeno-associated viral vectoranaloganterior chamberbasecanine modelclinical translationclinically relevantclinically translatablecollegecompliance behaviordesigngene therapygenetic architecturehuman modelmedical schoolsmedication complianceminimally invasivemouse modelnerve damagenormotensivenoveloptic nerve disorderovertreatmentpreventreceptortargeted treatmenttherapeutic effectivenesstherapy designtransgene expressiontranslational barrier
项目摘要
ABSTRACT
c
Sustained ocular hypertension in open angle glaucoma (OAG) and congenital glaucoma causes
degeneration of the optic nerve and death of retinal ganglion cells, leading to irreversible vision loss. Whilst
reducing intra-ocular pressure (IOP) using a combination of pharmacological and surgical approaches is
known to effectively prevent glaucoma progression, the therapeutic efficacy of such a strategy is critically
undermined by poor patient compliance, with fewer than 25% of patients maintaining treatment over a one-
year period. Owing to poor compliance and the need maintain a life-long daily treatment regimen,
glaucomatous patients regularly suffer bouts of uncontrolled ocular hypertension that dramatically increase
the risk of developing severe sight-threatening complications, even when diagnosed early. As a
consequence, there is a clear need to develop a long-acting therapy that lowers IOP without
requiring daily intervention. Herein we propose that IOP may be permanently and safely lowered using a
gene therapy strategy aimed at modifying cells of the cornea and aqueous humor outflow pathway (AHOP)
to synthesize and secrete prostaglandin F2α, (PGF2α), a drug that is known clinically to effectively lower IOP
in OAG patients when administered daily as an eye drop. We present robust preliminary data demonstrating
that cells of the cornea and AHOP can be effectively targeted using intracameral injection of recombinant
adeno-associated virus (rAAV) vector, that expression of prostaglandin F synthase (PTGS2) and
prostaglandin F receptor (PTGFR) catalyzes de novo biosynthesis and secretion of PGF2α into the aqueous
humor, and that this causes a highly significant, dose-dependent reduction in IOP that is maintained for over
12-months in normotensive animals. In this multi-PI application, we will evaluate the feasibility, safety and
long-term therapeutic efficacy of our novel gene therapy treatment in the Pitx2+/- mouse model of congenital
glaucoma (Aim 1) and the ADAMTS10 beagle model of OAG (Aim 2). Demonstrating the ability to
permanently lower IOP in glaucomatous eyes would represent a paradigm shift in the clinical management
of glaucoma by obviating the need for adherence to a daily treatment regimen and the data generated from
this work is expected to support clinical translation and the instigation of an investigator led clinical trial. The
Ocular Gene Therapy Laboratory of the Medical College of Wisconsin (MCW), directed by Dr Daniel
Lipinski (contact PI/PD), and the laboratory of Dr András Komáromy (PI/PD) at the College of Veterinary
Medicine at Michigan State University (MSU) provide the perfect environment in which to complete the
proposal. Finally, our proposal addresses an emerging need identified in the NEI Publication “Vision
Research: Needs, Gaps, and Opportunities” specifically: 1) Define the genetic architecture of glaucoma to
provide direct potential targets for therapy; 2) develop animal models that better approximate human
glaucoma and predict safety and efficacy of novel treatments.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andras Komaromy其他文献
Andras Komaromy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andras Komaromy', 18)}}的其他基金
Development of an IOP-lowering gene therapy treatment for glaucoma
开发治疗青光眼的降低眼压的基因疗法
- 批准号:
10630351 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy
全色盲 - 疾病机制和视锥细胞定向基因治疗
- 批准号:
7756614 - 财政年份:2009
- 资助金额:
$ 67.55万 - 项目类别:
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy
全色盲 - 疾病机制和视锥细胞定向基因治疗
- 批准号:
8446968 - 财政年份:2009
- 资助金额:
$ 67.55万 - 项目类别:
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy
全色盲 - 疾病机制和视锥细胞定向基因治疗
- 批准号:
7564888 - 财政年份:2009
- 资助金额:
$ 67.55万 - 项目类别:
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy
全色盲 - 疾病机制和视锥细胞定向基因治疗
- 批准号:
8212108 - 财政年份:2009
- 资助金额:
$ 67.55万 - 项目类别:
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy
全色盲 - 疾病机制和视锥细胞定向基因治疗
- 批准号:
8013792 - 财政年份:2009
- 资助金额:
$ 67.55万 - 项目类别:
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy
全色盲 - 疾病机制和视锥细胞定向基因治疗
- 批准号:
8011239 - 财政年份:2009
- 资助金额:
$ 67.55万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 67.55万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 67.55万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 67.55万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 67.55万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 67.55万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 67.55万 - 项目类别:














{{item.name}}会员




